Childhood cancers trials in Australia

In Australia 98 Also abroad 2459

98 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Where
Parkville, Randwick
Age
12 years and over
People
355 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00
Phase 2Taking people
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Where
Brisbane, North Adelaide
Age
1 year to 18 years
People
50 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07354074
Phase 1/2Taking people
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Where
Melbourne, Sydney, Woolloongabba
Age
12 years and over
People
840 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00
Phase 1/2Taking people
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Where
Nedlands, South Brisbane
Age
6 months to 30 years
People
65 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05533775
Phase 1/2Taking people
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
Where
Clayton, Perth, Southport
Age
2 years and over
People
420 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT04811560 · EU 2023-506581-31-00
Phase 2/3Taking people
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Where
Camperdown, Melbourne, Murdoch
People
1,541 worldwide
Run by
Celgene
See details and how to joinNCT03435796 · EU 2023-504201-36-00
Phase 3Taking people
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Where
Parkville, Perth, Randwick, South Brisbane, Westmead
Age
Up to 30 years
People
478 worldwide
Run by
National Cancer Institute (NCI)
See details and how to joinNCT06172296
Phase 1/2Taking people
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Where
Brisbane, Melbourne, Randwick
Age
6 months to 25 years
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00
Phase 1/2Taking people
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
Where
Parkville, Randwick
Age
1 month to 17 years
People
134 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07630974 · EU 2025-522339-32-00
Phase 1Taking people
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
Where
Camperdown, Melbourne, Nedlands
Age
2 years and over
People
50 worldwide
Run by
Amgen
See details and how to joinNCT07297979
Phase 2Taking people
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Where
Hunter Regional Mail Centre, Parkville, Perth, South Brisbane
Age
366 days to 46 years
People
222 worldwide
Run by
National Cancer Institute (NCI)
See details and how to joinNCT06124157
Phase 2Taking people
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
Where
Melbourne, Perth, Randwick, South Brisbane
Age
12 months to 39 years
People
60 worldwide
Run by
Nationwide Children's Hospital
See details and how to joinNCT06838676
Phase 1/2Taking people
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Where
Fitzroy, Perth
Age
16 years and over
People
85 worldwide
Run by
AstraZeneca
See details and how to joinNCT07155226 · EU 2025-521299-76-00
Phase 3Taking people
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Where
Douglas, Gosford, Kingswood, Kogarah, Melbourne, Nedlands, Parkville, Perth, Randwick, South Brisbane, Wollongong
Age
12 years and over
People
468 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00
Phase 3Taking people
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
Where
Adelaide, Chermside, Melbourne, Murdoch, Westmead
People
115 worldwide
Run by
Pierre Fabre Medicament
See details and how to joinNCT03394365 · EU 2024-516622-57-00
Phase 3Taking people
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Where
Adelaide, Clayton, New Lambton Heights, Parkville, Perth, South Brisbane, Sydney, Westmead
Age
1 day to 1 year
People
160 worldwide
Run by
Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT05327894 · EU 2022-502503-30-00
No phaseTaking people
Investigating the Efficacy of a Paediatric Fertility Preservation Decision Aid in Parents and Adolescents and Young Adults (CAYA) Cancer Survivors
Where
Melbourne
Age
16 years and over
People
358
Run by
Murdoch Childrens Research Institute
See details and how to joinNCT06894810
Phase 1/2Taking people
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
Where
Melbourne
Age
12 years and over
People
83 worldwide
Run by
AstraZeneca
See details and how to joinNCT07109219 · EU 2025-522372-93-00
Phase 1/2Taking people
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Where
Sydney
Age
1 year to 30 years
People
50 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07387926
Phase 2Taking people
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Where
Hunter Regional Mail Centre
Age
Up to 21 years
People
50 worldwide
Run by
National Cancer Institute (NCI)
See details and how to joinNCT06064097
Phase 1/2Taking people
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Where
Melbourne
Age
12 years and over
People
255 worldwide
Run by
AstraZeneca
See details and how to joinNCT06137118 · EU 2023-505840-20-00
Phase 1/2Taking people
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Where
Adelaide, Birtinya, Fitzroy, Nedlands, South Brisbane, Waratah
Age
12 years and over
People
161 worldwide
Run by
AstraZeneca
See details and how to joinNCT06137144 · EU 2023-506747-42-00
Phase 1/2Taking people
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Where
Melbourne, Nedlands, Parkville, Saint Leonards
Age
30 days and over
People
447 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT04065399 · EU 2024-513759-34-00
Phase 2/3Taking people
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Where
Bedford Park, Box Hill, Chermside, Frankston, Wollongong
Age
18 years and over
People
740 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00
Phase 1/2Taking people
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Where
Brisbane, Parkville, Sydney
Age
1 month to 17 years
People
50 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06941272 · EU 2024-518771-66-00